Skip to main content
Journal cover image

319 The tumor-intrinsic NLRP3 inflammasome establishes a pulmonary metastatic niche via type II epithelial HSP70/TLR4 signaling and facilitates disease hyperprogression in response to immunotherapy

Publication ,  Conference
Theivanthiran, B; Liu, F; DeVito, N; Plebanek, M; Hanks, B
Published in: Journal for ImmunoTherapy of Cancer
November 2021

Duke Scholars

Published In

Journal for ImmunoTherapy of Cancer

DOI

EISSN

2051-1426

Publication Date

November 2021

Volume

9

Issue

Suppl 2

Start / End Page

A343 / A343

Publisher

BMJ

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Theivanthiran, B., Liu, F., DeVito, N., Plebanek, M., & Hanks, B. (2021). 319 The tumor-intrinsic NLRP3 inflammasome establishes a pulmonary metastatic niche via type II epithelial HSP70/TLR4 signaling and facilitates disease hyperprogression in response to immunotherapy. In Journal for ImmunoTherapy of Cancer (Vol. 9, pp. A343–A343). BMJ. https://doi.org/10.1136/jitc-2021-sitc2021.319
Theivanthiran, Balamayooran, Fang Liu, Nicholas DeVito, Michael Plebanek, and Brent Hanks. “319 The tumor-intrinsic NLRP3 inflammasome establishes a pulmonary metastatic niche via type II epithelial HSP70/TLR4 signaling and facilitates disease hyperprogression in response to immunotherapy.” In Journal for ImmunoTherapy of Cancer, 9:A343–A343. BMJ, 2021. https://doi.org/10.1136/jitc-2021-sitc2021.319.
Theivanthiran, Balamayooran, et al. “319 The tumor-intrinsic NLRP3 inflammasome establishes a pulmonary metastatic niche via type II epithelial HSP70/TLR4 signaling and facilitates disease hyperprogression in response to immunotherapy.” Journal for ImmunoTherapy of Cancer, vol. 9, no. Suppl 2, BMJ, 2021, pp. A343–A343. Crossref, doi:10.1136/jitc-2021-sitc2021.319.
Journal cover image

Published In

Journal for ImmunoTherapy of Cancer

DOI

EISSN

2051-1426

Publication Date

November 2021

Volume

9

Issue

Suppl 2

Start / End Page

A343 / A343

Publisher

BMJ

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology